Nearly all of the patients who responded to the a personalized mRNA pancreatic vaccine are still alive six years later.

New data finds an experimental cancer treatment is showing major promise. Our team spoke with the first person to receive a ...

Moderna (NasdaqGS:MRNA) plans to present Phase 1/2 data for its mRNA-4359 cancer antigen therapy combined with pembrolizumab ...

The U.S. FDA has granted Fast Track designation for mRNA-4359 in combination with pembrolizumab for the treatment of ...

The advent of mRNA vaccines against SARS-CoV-2 in 2020 changed the course of the COVID-19 pandemic. Now, the Nobel ...

WashU Medicine researchers have described how mRNA cancer vaccines engage the immune system, through an unconventional pathway involving two subsets of immune cells called dendritic cells.

Among adolescents and young adults, cTnI levels remain within normal ranges after mRNA-1273 vaccination, with no evidence of increased myocardial injury.

Katalin Karikó, a Nobel Prize-winning scientist who pioneered mRNA research that led to life-saving vaccines during the COVID ...

WASHINGTON (AP) — So-called mRNA vaccines saved millions of lives during the COVID-19 pandemic — and now scientists are using that Nobel Prize-winning technology to try to develop vaccines and ...

Secretary Robert F. Kennedy Jr. said his department would slash funding for mRNA vaccine research and shift its focus to "whole-virus" and "universal vaccines" instead. Secretary Robert F. Kennedy Jr.

Moderna (MRNA) closed at $54.26 in the latest trading session, marking a +2.69% move from the prior day. This change outpaced the S&P 500's 0.8% gain on the day. Meanwhile, the Dow lost 0.15%, and the ...

BioNTech envisioned the site making hundreds of millions of vaccines a year, but has since shifted its pipeline to other modalities while mRNA technology continues to face headwinds in the U.S.